Back to News
Market Impact: 0.25
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Georgiamune and Menarini Group announced an exclusive global license and collaboration agreement for GIM-621, described as a first-in-class oral immuno-oncology agent. The provided text gives no financial terms, development milestones, or clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Asia stocks fall as AI rout batters S.Korea; Japan spooked by strong CPI
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Why is SK Hynix stock sliding today?
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Gold Holds Near Three-Month Low as AI Jitters Fuel Volatility
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors